Health Insurance (Section 3C Diagnostic Imaging Services – Whole Body Magnetic Resonance Imaging Scan) Determination 2022

The instrument works by reference and incorporation, not by standalone prescription. Key legal and operational concepts in the text are:

• Authority and legal basis: The determination is made under subsection 3C(1) of the Health Insurance Act 1973 (cl 3). It therefore operates within the statutory machinery that permits the Minister to specify health services for the purposes of the Act.

• Relevant service and clinically relevant service: The instrument uses the term “relevant service” as shorthand for a health service defined in subsection 3C(8) of the Act, and it requires that the service be provided “in accordance with this instrument and as a clinically relevant service” for the treatment in cl 5 to apply (cl 4(1); cl 5). The note in cl 4(1) also reminds users that “clinically relevant service”, “diagnostic imaging services table”, “item” and “professional service” are defined in s 3(1) of the Act.

• Treatment-as-if mechanism: Clause 5 is the operative conversion mechanism. It directs that, for the “relevant provisions”, the specified relevant service is to be treated both as a professional service and a diagnostic imaging service, and as if there were an item in the diagnostic imaging services table that relates to the service and specifies a fee per State equal to the Schedule amount (cl 5(a)-(b)). This is a legal fiction used to bring the service within the payment and regulation architecture already governing other imaging items.

• Schedule specification: The Schedule supplies Item 63564, its description and a fee of $1,655.20 (Schedule, Columns 1-3). The Schedule also prescribes gating conditions for clinical eligibility: request by a specialist or consultant physician in consultation with a clinical geneticist in a familial cancer or genetic clinic, and an express identification in the request that the patient is at high risk due to heritable TP53‑related cancer syndrome (Schedule, Description).

• Cross‑references to the diagnostic imaging services table: The instrument explicitly links certain shorthand notations and operational clauses back to the diagnostic imaging services table. For example, the symbol “(R)” is given the meaning provided by clause 1.2.15(1) of the diagnostic imaging services table (cl 4(1)). Clause 6(1) says clause 1.2.17 of that table shall have effect as if the items in Schedule 1 were specified for the purpose of that clause. The instrument therefore depends on the content and operation of those diagnostic imaging services table clauses.

• Frequency limitation: Clause 7(1) imposes an explicit 12‑month frequency limitation on the use of item 63564 for the same patient.

• Dynamic operation: Clause 4(2) provides that, unless a contrary intention appears, references to provisions of the Act, the National Health Act 1953 or their regulations are to be read as those provisions “as in force from time to time”. That means future amendments to the referenced Acts and regulations will apply to this determination unless the determination itself is later amended.

These concepts together mean the instrument does not itself create a new standalone payment program. Instead it folds a narrowly defined clinical service into the existing diagnostic imaging item and payment framework by specifying an item number, clinical gating criteria and a fee, and by applying relevant clauses of the diagnostic imaging services table to that item.

The instrument affects identifiable groups; the causal mechanics are set out below with textual references.

• Patients with hTP53rc: The Schedule limits the clinical population to patients identified in a request as having a high risk of developing cancer due to heritable TP53‑related cancer (hTP53rc) syndrome (Schedule, Description). Only such patients, when otherwise eligible and meeting the other conditions of the Schedule and the Act, can be the subject of item 63564 claims.

• Referring clinicians: The Schedule requires that the MRI whole body scan be “requested by a specialist or consultant physician in consultation with a clinical geneticist in a familial cancer or genetic clinic” (Schedule, Description). That condition places an administrative and clinical gate on who can initiate the item; diagnosticians, general practitioners and other referrers who are not specialists or consultant physicians, or who do not consult a clinical geneticist, will not meet the Schedule’s referral requirement.

• Clinical geneticists and familial cancer/genetic clinics: The Schedule makes consultation with a clinical geneticist in a familial cancer or genetic clinic a precondition of the request. Those clinicians and clinics therefore acquire an effective gatekeeping role: their consultation must be recorded or evident in the request for the item to apply.

• Diagnostic imaging providers: Radiology and MRI providers who deliver whole body MRI scans will be affected because the instrument creates a distinct item number (63564) and fee ($1,655.20) that must be used when the Schedule conditions are satisfied. Providers will need to ensure accurate billing, documentation and compliance with the frequency limitation in cl 7 to claim the item.

• Medicare administration and payers: By treating the service as an item in the diagnostic imaging services table for “relevant provisions”, the instrument brings claims for these scans within the Medicare benefits and compliance framework (cl 5). Administrators will need to map item 63564 into claim processing systems and apply the Act’s rules for processing, auditing and, where necessary, recovering payments.

• Insurers and private payers: Although the instrument itself does not reference private health insurance directly, providers and patients may have to determine whether private insurers will cover the scan or whether co‑payments arise. The instrument’s specified fee provides an explicit per‑claim figure that will be relevant to insurer negotiations and patient billing.

• Health services auditors and compliance officials: The Schedule places documentary requirements on requests (specialist/consultant physician request, consult with clinical geneticist, identification of hTP53rc risk). Auditors and compliance officers will have to check that those conditions were met when item 63564 is claimed, and that the 12‑month limit in cl 7(1) is respected.

• State-level relevance: The fee is stated as being specified “in relation to each State” in the Schedule and cl 5(b)(ii) requires the fee to be specified for each State (cl 5(b)(ii) and Schedule, Column 3). Administratively this means the item applies uniformly across States for the purposes of the Act, and providers in any State will use the same item and fee.

Groups not directly affected by the instrument include patients without hTP53rc risk, referrers who cannot satisfy the specialist/geneticist consultation requirement, and claims that do not meet the documentation requirements. The instrument does not create an entitlement for all MRIs or for MRIs used for other indications; it is narrowly targeted to whole body MRI for early detection of cancer in the hTP53rc population as described in the Schedule.

The instrument creates duties and rights through treatment of the specified service as an item, the Schedule’s clinical gating criteria and the frequency limitation. These follow directly from the operative clauses.

Duties imposed on clinicians and referrers

• Specialist or consultant physician involvement: The Schedule requires that the MRI be “requested by a specialist or consultant physician” (Schedule, Description). A duty therefore exists for a referrer to be a specialist/consultant physician where item 63564 is to apply.

• Consultation with a clinical geneticist in a familial cancer or genetic clinic: The Schedule requires that the specialist or consultant physician request be made “in consultation with a clinical geneticist in a familial cancer or genetic clinic” (Schedule, Description). That places a duty on referrers to consult with the named class of clinician and clinic prior to requesting the item.

• Identification of high risk due to hTP53rc: The request must “identify[] that the patient has a high risk of developing cancer malignancy due to heritable TP53‑related cancer (hTP53rc) syndrome” (Schedule, Description). The duty is to include that identification in the request documentation.

Duties imposed on providers and billing administrators

• Use of item number and fee: Clause 5 requires the service to be treated as if there were an item in the diagnostic imaging services table with the fee “specified in the Schedule in relation to the service” (cl 5(b)(ii)). Providers who claim the Medicare benefit must therefore use item 63564 and the associated fee coding where appropriate.

• Frequency limitation: Clause 7(1) imposes a duty to ensure item 63564 is not claimed where the same patient has received a service to which the same item applies within the preceding 12 months. Providers and administrators must check prior claims and patient records to comply.

Rights and entitlements

• Treatment as a professional and diagnostic imaging service: Clause 5(a) treats the relevant service as both a professional service and a diagnostic imaging service for the “relevant provisions”. That confers the legal status (for the purposes of the Act and related provisions) that makes the service eligible for the administrative processes, benefits and regulation that apply to professional and diagnostic imaging services under the Act and the National Health Act 1953 (cl 5(a)). The instrument does not itself set rebate amounts; the rights to claim are exercised within the “relevant provisions” that govern payment.

• Access limited by Schedule criteria: Patients who meet the Schedule criteria have a right to have the service treated under the diagnostic imaging regime through item 63564, subject to any applicable payment and audit rules in the “relevant provisions” (cl 5). That right is conditional and administrative.

Procedural and compliance rights/duties

• Cross‑reference obligations: The instrument refers to meanings and operational clauses in the diagnostic imaging services table (for example, (R) meaning at cl 4(1), and cl 6(1) making clause 1.2.17 applicable). Clinicians and administrators have the duty to consult those cross‑referenced provisions to understand procedural obligations (for example, what (R) requires in practice).

• Dynamic incorporation: Clause 4(2) means that duties and rights that arise from the Act, the National Health Act 1953 or their regulations are to be taken as those provisions “as in force from time to time”. Parties must therefore monitor changes to those Acts and regulations to understand evolving duties and rights.

What the instrument does not do (limits on duties/rights)

• It does not itself create new criminal penalties or separate enforcement mechanisms; it makes the service subject to the “relevant provisions” (cl 5 and cl 4(1)). Any enforcement, audit remedies, civil penalties or recovery powers operate under those underlying statutes and regulations rather than under the determination itself.

• It does not state Medicare rebate percentages, patient co‑payments or private insurance coverage. Those financial outcomes are determined under the Act’s payment rules and any applicable insurance arrangements.

In sum, the instrument imposes duties on referrers and providers to meet specified clinical and documentary conditions to use item 63564, grants the right to have the service treated under the diagnostic imaging/Act framework where those conditions are met, and ties the operation of those duties and rights to the broader “relevant provisions” and to certain diagnostic imaging services table clauses.

The determination itself does not create standalone penalties or an independent enforcement regime. The text instead places the specified relevant service within the ambit of the Act’s existing statutory machinery for medical services and diagnostic imaging items. The enforcement and penalty consequences therefore derive from the “relevant provisions” as defined in cl 4(1), which are “all provisions, of the Act and regulations made under the Act, and the National Health Act 1953 and regulations made under the National Health Act 1953, relating to medical services, professional services or items.”

Practical implications from the wording

• Enforcement will operate through existing Act and regulations: Because cl 5 treats the service “for the relevant provisions, as if” it were both a professional and diagnostic imaging service and as if there were an item specifying the fee, any contraventions (for example, fraudulent claims, inappropriate billing, failure to meet documentation requirements) will be dealt with under the enforcement, audit, penalty and recovery provisions that apply to other items under the Act and the National Health Act 1953. The instrument itself does not add a separate penalty regime.

• Audit and documentation review: The Schedule requires that the request identifies hTP53rc risk and that the request be made by a specialist/consultant physician in consultation with a clinical geneticist in an appropriate clinic. Auditors reviewing claims for item 63564 will therefore examine referral documentation and records of consultation to establish eligibility. Failure to demonstrate compliance can be addressed through existing audit and recovery powers under the relevant Acts.

• Potential civil and administrative remedies available under the relevant provisions: The Act and the National Health Act 1953 contain mechanisms for recovering improperly paid benefits, imposing civil penalties, and in some circumstances prosecuting fraud. The determination’s text brings item 63564 within that pre‑existing framework by treating the service as an item for the relevant provisions.

• Frequency enforcement: Clause 7(1) creates a discrete operational constraint: item 63564 applies only if the same patient has not received a service to which the same item applies within the preceding 12 months. Administrative systems and auditors can use this clause as a specific basis for disallowing or recovering payments for duplicate or too‑frequent claims.

Unstated enforcement features that users must attend to

• The instrument does not detail the evidentiary threshold for demonstrating consultation with a clinical geneticist, the format of the identification of hTP53rc risk, or what documentary proof auditors will accept. Those evidentiary and procedural details will typically be supplied by the diagnostic imaging services table clauses referenced (for example, the meaning of (R) in clause 1.2.15(1) of that table) and by established Medicare audit practice under the Act.

• The instrument’s dynamic incorporation clause (cl 4(2)) means that changes to the Act or the National Health Act 1953, or their regulations, can alter the enforcement landscape for this item without amendment to the determination itself.

In short, enforcement is delegated to the existing legal and administrative apparatus for Medicare items. The determination places item 63564 within that apparatus and thereby exposes claims to the same audit, recovery and penalty tools that apply to other diagnostic imaging items.

The determination is expressly designed to work through and within the architecture of the Health Insurance Act 1973 and the National Health Act 1953 and their regulations. The instrument makes multiple explicit cross‑references; these determine its legal interactions.

Direct statutory cross‑references

• Made under the Act: The instrument is made under subsection 3C(1) of the Health Insurance Act 1973 (cl 3). That provision is the statutory basis that permits the specification of health services for Medicare purposes. The determination therefore operates as a subordinate instrument within the Act’s delegated‑legislation framework.

• Relevant provisions defined expansively: Clause 4(1) defines “relevant provisions” to include all provisions of the Act and regulations made under the Act, and the National Health Act 1953 and regulations under it, that relate to medical services, professional services or items. By using that term in cl 5, the determination ties the new item directly into the substantive and procedural rules across both statutes and their regulations.

• Incorporation of diagnostic imaging services table clauses: The instrument invokes specific clauses of the diagnostic imaging services table. For example, (R) is given the meaning in clause 1.2.15(1) of the diagnostic imaging services table (cl 4(1)). Clause 6(1) makes clause 1.2.17 of that table apply as if the items in Schedule 1 were specified for that clause. The instrument therefore operates in tandem with the diagnostic imaging services table, and its practical operation depends on the content of those clauses.

Dynamic references

• “As in force from time to time”: Clause 4(2) directs that references to provisions of the Act or the National Health Act 1953, or related regulations, are to be read as those provisions “as in force from time to time”. This means the determination’s operation is dynamic: amendments to the referenced Acts or regulations will affect how the item functions without the need to amend this instrument expressly.

Interplay with payment and audit rules

• Payment rules and benefit entitlements: Clause 5 treats the service as an item in the diagnostic imaging services table with a specified fee. That means payment entitlement, rebate calculations, patient contributions, and related rules are governed by the payment and benefit provisions in the Act, the National Health Act 1953 and their regulations. The determination itself does not set rebate rates or patient liability; it defers to those provisions.

• Audit, recovery and penalties: As noted under penalties and enforcement, the mechanism for dealing with non‑compliance is the underlying statutory and regulatory framework. Thus the determination interacts with recovery powers, civil sanctions and criminal offences established in the Act and the National Health Act 1953.

Limited scope relative to other laws

• The instrument is narrowly targeted to a single defined clinical service (whole body MRI for early cancer detection in hTP53rc patients). It does not purport to change other regulatory regimes such as health practitioner registration, radiology facility licensing, radiation safety laws or state hospital funding arrangements. However, providers must still comply with those separate regulatory obligations; the determination does not displace or alter them.

Practical consequence of the interactions

• Operators and legal advisers must read this instrument together with the diagnostic imaging services table and the “relevant provisions” of the two Acts and their regulations to understand the full set of obligations, benefits and enforcement consequences. The determination is a node in an existing statutory network rather than an isolated source of law.

The instrument as provided is titled and dated as the Health Insurance (Section 3C Diagnostic Imaging Services - Whole Body Magnetic Resonance Imaging Scan) Determination 2022 (cl 1). The text of the instrument does not itself record any prior amendments, revocations or a history of changes. It does not attach an explanatory memorandum or legislative history in the text provided. The operative features we can record from the instrument are:

• Date and identification: The instrument identifies itself (cl 1) as the 2022 Determination. No further timing or commencement clause is included in the supplied text; the instrument does not state a separate commencement clause or transitional arrangements.

• Dynamic operation clause: Clause 4(2) provides that references to provisions of the Act or the National Health Act 1953 or their regulations are to be read “as in force from time to time”. This is an ongoing mechanism by which future amendments to those Acts and regulations will affect the operation of the determination without requiring the determination itself to be amended.

• No listed amendments within the instrument: The supplied instrument text does not include a schedule of amendments or citations of amending instruments. It also does not indicate that it repeals or replaces any earlier determinations.

What users should do to trace amendment history

• Check the Federal Register or the legislative instrument register and the consolidated Health Insurance Act 1973 materials: Because the instrument is subordinate legislation under the Act, any later changes, revocations or replacements will appear in the legislative instrument register or other official gazettes. The instrument’s own text does not provide that history.

• Monitor changes to cross‑referenced provisions: Given the dynamic incorporation in cl 4(2), changes to the diagnostic imaging services table clauses referenced (for example, clause 1.2.15(1) and clause 1.2.17) will alter how the determination operates. To understand amendment effects, one must review the amended diagnostic imaging services table and related regulations.

In short, the instrument is presented as the 2022 Determination. There are no internal amendment notations in the provided text; any amendment history or later variations will need to be traced through the official instrument registers and the Act’s consolidated text.

The instrument does not record any litigation, judicial review, or case law relating to it. The text contains no references to court decisions, no transitional litigation provisions and no judicial commentary. The Schedule and operative clauses are presented as a statutory instrument that will be applied administratively under the Act. Therefore:

• There are no cases cited in the instrument text, and no litigation history is embedded in the instrument.

• Because the determination operates by bringing the item within the Act’s existing enforcement and recovery framework (see cl 5 and cl 4(1)), any future litigation that concerns item 63564 is likely to arise under the Act or the National Health Act 1953,for example, in disputes about appropriate documentation, eligibility, audit recoveries or alleged fraud,but the instrument itself does not identify any such proceedings.

What to monitor

• Administrative reviews and tribunal decisions: If a claim for item 63564 is audited or disallowed, internal review or administrative tribunal processes under the Act or the regulations may be used. Those decisions, if litigated or appealed, will be the source of any subsequent case law.

• Potential judicial review on procedural or jurisdictional grounds: Challenges might arise in future about whether the instrument was validly made under subsection 3C(1) of the Act, or whether administrative decisions applying the item were lawful. Again, there is no litigation record in the instrument; tracking such developments requires monitoring courts and tribunals after the instrument’s operation commences.

Given the absence of litigation references in the text, the instrument offers no directive about current case law; users must look beyond the instrument to judicial databases and administrative decisions for any emergent litigation history.

The instrument contains several drafting features and cross‑references that create practical pitfalls for clinicians, providers and billing administrators. These are matters where compliance risks, misinterpretation, or administrative failure could arise if the textual details and cross‑references are not followed precisely.

1. Narrow clinical eligibility and strict referral gate

• The Schedule requires request by “a specialist or consultant physician in consultation with a clinical geneticist in a familial cancer or genetic clinic” (Schedule, Description). A simple referral from a general practitioner or a direct patient self‑referral will not meet the Schedule’s textual condition. Providers who accept such referrals and bill item 63564 risk audit disallowance.

2. Requirement to identify hTP53rc risk in the request

• The request must explicitly “identify[] that the patient has a high risk of developing cancer malignancy due to heritable TP53‑related cancer (hTP53rc) syndrome” (Schedule, Description). Vague or undocumented assertions about genetic risk without clear evidence or documentation of the risk and of the consultation may be insufficient for audit purposes.

3. Consultation documentation standards are unspecified

• The instrument mandates consultation with a clinical geneticist but does not specify the form, timing, or content of that consultation note. Auditors may require contemporaneous records, signed notes or clinic stamps; the instrument itself does not supply these standards. Providers should not assume informal electronic communication suffices without documentary proof.

4. (R) and (Anaes.) shorthand are cross‑referenced

• The Schedule ends with “(R) (Anaes.)” after the description. Clause 4(1) tells us that “(R)” has the meaning given by clause 1.2.15(1) of the diagnostic imaging services table. The practical obligations encoded by (R) (for example, whether it requires reporting, remedial steps, or an additional code) are not in this instrument and must be checked in the diagnostic imaging services table. Similarly, “Anaes.” likely indicates an anaesthesia component or annotation; the instrument does not explain billing implications for anaesthesia services.

5. Annual frequency limit

• Clause 7(1) provides that item 63564 applies only if the same patient has not received a service to which the same item applies within the preceding 12 months. This is a strict calendar limitation. Failure to check prior claims (especially across providers) risks duplicate claims that can be disallowed and recovered.

6. Fee is specified but rebate mechanics are not

• The Schedule sets a fee of $1,655.20 (Schedule, Column 3). The instrument does not state the Medicare rebate amount or patient co‑payment. Confusion can arise if providers assume the fee equals the rebate. Billing staff must consult the diagnostic imaging services table and the Act’s payment rules to determine the rebate and out‑of‑pocket cost implications.

7. Dynamic reliance on external clauses

• Clause 6(1) applies clause 1.2.17 of the diagnostic imaging services table “as if” the Schedule items were specified for that clause. The practical effect of this is contingent on the content of clause 1.2.17. Providers who do not review clause 1.2.17 may miss procedural requirements or limitations applied through that clause.

8. The instrument does not itself alter other regulatory obligations

• Radiology practice, facility accreditation, radiation safety, and practitioner registration obligations remain governed by separate state and federal laws. Reliance on this instrument alone for compliance is insufficient.

9. State fee specification language

• Clause 5(b)(ii) requires the fee to be specified for each State. The Schedule provides a single fee figure. Practitioners should verify that their jurisdictional billing systems map the Schedule fee correctly to their State’s coding and billing processes.

10. No explicit commencement or transitional provisions in the supplied text

• The instrument text provided does not include a commencement date or transitional provisions. Users must verify the instrument’s commencement and any transitional rules in the official legislative instrument publication to ensure correct claim timing.

Collectively, these “gotchas” are largely documentary and procedural: accurate referral and consultation documentation, strict adherence to the item’s clinical gate, correct application of the annual limit, and checking the diagnostic imaging services table for auxiliary operational rules. Providers should not assume broad clinical discretion or that the instrument supplies all evidentiary standards; instead, they must read the instrument together with the diagnostic imaging services table and the relevant parts of the Act and National Health Act 1953.

Compliance with this determination requires clinicians, clinics and billing administrators to translate the instrument’s textual conditions into concrete administrative and clinical processes. Below are operational steps to reduce audit and payment risk, each grounded in the instrument’s clauses.

1. Confirm clinical eligibility before scheduling or billing

• Ensure the patient is identified in the request as having “a high risk of developing cancer malignancy due to heritable TP53‑related cancer (hTP53rc) syndrome” as required by the Schedule. Document the genetic diagnosis or the clinical genetics assessment that supports the hTP53rc risk statement.

• Verify that the clinical indication aligns with “MRI - whole body scan for the early detection of cancer” as described in the Schedule.

(Authority: Schedule, Description; cl 5)

2. Ensure the request comes from the correct referrer and involves the required consultation

• The request must be “by a specialist or consultant physician in consultation with a clinical geneticist in a familial cancer or genetic clinic” (Schedule, Description). Before claiming item 63564, secure and retain evidence that the referral came from a specialist or consultant physician and that the referral was made in consultation with a clinical geneticist.

• Document the consultation: include the clinical geneticist’s name, clinic affiliation (familial cancer or genetic clinic), date of consultation, and brief note of agreement to the referral. Use clinic letterheads, signed consultation notes, or electronic medical record entries that meet your usual audit standards.

(Authority: Schedule, Description)

3. Use the correct item number and fee in billing systems

• When claiming under Medicare, use item 63564 as provided in the Schedule and ensure the claim references the fee structure as appropriate for your State mapping.

• Do not assume the Schedule fee equals the Medicare rebate. Rebate entitlements and patient co‑payments are governed by the Act and the diagnostic imaging services table; confirm rebate calculations with Medicare payment rules and your billing software.

(Authority: cl 5(b)(ii); Schedule, Column 3)

4. Observe the 12‑month frequency limitation

• Implement an administrative check in pre‑authorisation or scheduling systems to establish whether the patient has received item 63564 (or a service to which the same item applies) within the preceding 12 months. If such a service exists, do not claim item 63564.

• Maintain a searchable index of prior imaging items per patient to support this check.

(Authority: cl 7(1))

5. Record and retain documentary evidence

• Keep the full referral, geneticist consultation note, the patient’s genetic test results or clinical genetics assessment supporting hTP53rc risk, the imaging report, and the billing claim documentation. Retain documents in accordance with Medicare audit retention expectations.

• Where (R) is included in the Schedule, consult clause 1.2.15(1) of the diagnostic imaging services table to identify any additional documentation or reporting obligations that accompany that notation.

(Authority: cl 4(1) and Schedule, (R); cl 6(1) re diagnostic imaging table clauses)

6. Check and follow diagnostic imaging services table cross‑references

• Clause 6(1) makes clause 1.2.17 of the diagnostic imaging services table applicable as if the Schedule items were specified for that clause. Review clause 1.2.17 (and clause 1.2.15(1) for the meaning of (R)) to identify applicable clinical or administrative rules, including any pre‑authorisation, reporting, or coding obligations.

(Authority: cl 6(1); cl 4(1))

7. Coordinate with anaesthesia and ancillary services

• The Schedule includes the annotation “(Anaes.)”. Confirm whether anaesthesia services associated with the scan require separate itemisation or specific documentation and whether any anaesthesia claims interact with item 63564. Ensure anaesthesia providers document consent and monitoring consistent with their own practice obligations.

(Authority: Schedule, (Anaes.))

8. Train staff and update protocols and IT systems

• Update referral forms, imaging requisition templates and electronic health records to capture the specific fields required by the Schedule: referrer identity (specialist/consultant), clinical geneticist consultation details, and explicit statement of hTP53rc high risk.

• Update billing systems to include item 63564 and to enforce a pre‑claim check for the 12‑month limitation.

(Authority: cl 5; cl 7(1); Schedule)

9. Prepare for audits and disputes

• Anticipate that claims for item 63564 will be subject to the same audit and recovery powers that apply to other diagnostic imaging items under the Act and the National Health Act 1953. Adopt an audit‑ready posture: organise records, retain consultation notes and genetic information (in compliance with privacy law), and create a standard file packet for each claim.

(Authority: cl 5; cl 4(1), defining “relevant provisions”)

10. Keep monitoring legislative and regulatory changes

• Because cl 4(2) incorporates references “as in force from time to time”, monitor amendments to the Health Insurance Act 1973, the National Health Act 1953, their regulations and the diagnostic imaging services table (including clauses 1.2.15(1) and 1.2.17) to identify changes that may affect documentation, claim processing or eligibility criteria.

(Authority: cl 4(2); cl 6(1))

Following these steps aligns operational practice with the instrument’s textual requirements. Providers should also coordinate with Medicare compliance officers or legal counsel to interpret diagnostic imaging table cross‑references and to reconcile the Schedule fee with rebate and co‑payment rules under the Act.